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Introduction
The identification of a highly effective malaria vaccine that pre-
vents disease in the great majority of vaccinees remains an elusive 
goal. However, recent data indicate that this major contribution to 
global public health should be achievable with the further devel-
opment of approaches that are already in clinical assessment. Of 
the many candidate vaccines that have entered clinical efficacy 
testing for P. falciparum malaria, at least 25 in total, only two 
approaches have provided unequivocal evidence of some pro-
tective efficacy in humans. One approach, targeting antibodies 
against the central repeat of the circumsporozoite protein has led 
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The difficulty of inducing protective immunity through antibod-
ies against sporozoites led to efforts to assess vectored vac-
cines as a means of inducing protective T-cell immunity against 
the malaria liver-stage parasite. Although DNA vectored vac-
cines used alone were poorly immunogenic and not protective, 
high levels of parasite clearance in the liver has been achieved 
with viral vectored vaccines used in heterologous prime-boost 
regimes. Such vectored vaccination regimes represent one of 
only two approaches that have induced repeatable partial ef-
ficacy in human P. falciparum subunit vaccine trials. Interestingly, 
vectors expressing the TRAP antigen have been consistently 
been more immunogenic and protective than vectors express-
ing the circumsporozoite protein in human trials. However, 
sterile protection requires induction of very potent T-cell re-
sponses that are currently only achievable with heterologous 
prime-boost regimes. Recently, simian adenoviruses have been 
assessed as priming agents in Adenovirus-MVA regimes in both 
phase I and phase IIa trials in the UK, based on very promising 
pre-clinical results showing better immunogenicity and efficacy 
than previous prime-boost regimes. The same vectors are also 
being assessed clinically expressing blood-stage antigens, at-
tempting to induce both protective antibodies and T cells as 
recently demonstrated in murine efficacy studies. These viral 
vectors now provide a major option for inclusion in a high effi-
cacy multi-stage malaria vaccine that should achieve deployable 
levels of efficacy in endemic settings.
review
to the development of RTS,S/AS01,1,2 which is now in a phase III 
clinical trial, aiming for partial efficacy of the order of 30–50% 
with durability of perhaps a year. The other approach is the sub-
ject of this review, the induction of protection using viral vector 
vaccines. Importantly, although viral vectors have been shown 
to induce significant protection by targeting the TRAP antigen 
expressed during the liver-stages there is now considerable interest 
in the possibility that vectors could induce significant protection 
by targeting blood-stage antigens as well.3,4
The first evidence that vectors could provide protection in 
humans came from a phase IIa challenge study using the orthopox 
vector NYVAC that encoded seven malaria antigens, including 
TRAP and CSP.5 Although antibody immunogenicity was poor, 
detectable lytic T-cell responses were found to TRAP, CSP and 
LSA-1 peptides, and 1 out of 35 challenged volunteers was sterilely 
protected. Use of TRAP with a polyepitope string, the ME.TRAP 
insert, was then assessed in DNA and MVA vectors both alone 
and in heterologous prime boost regimes. Significant reductions 
in parasite burden in the liver, estimated as approximately an 
80% reduction,6 were measured in vaccinees receiving DNA-
MVA regimes but not repeated doses of the single vectors.7,8 Using 
ex vivo ELISPOT assays the mean response measured after two 
DNA priming immunisations and an MVA boost was about 450 
SFU per million. In that study one out of eight vaccinees was ster-
ilely protected8 and in another, using related DNA-MVA regimes, 
there was a significant delay in time to patency.7 Subsequent eval-
uation of a fowlpox strain, FP9, as an alternative priming agent to 
DNA showed that two out of sixteen vaccinees were sterilely pro-
tected with an estimated 90% reduction in parasite burden in the 
liver.6,9 Field testing of the potential these regimes,10,11 particularly 
the latter was impeded by an unexpected drop in the potency of 
the vaccines when administered to 1–6 year old children amongst 
whom about 70% showed patent parasitaemia, a factor associated 
with reduced responses.11,12 Mean T-cell responses were of the 
order of 400–500 SFU/million in the phase IIa studies in the UK 
but four times lower in a Kenyan phase IIb trial in children where 
no efficacy was observed.13 Importantly in the phase IIa sporozoite 
challenge studies a clear correlation of T-cell responses measured 
by either ex vivo9 or cultured14 ELISPOT assays was observed 
with protection, the latter measured as either delay in time to 
patency or reduction in liver-stage parasite burden. Estimates of 
the magnitude of ex vivo ELISPOT responses required for sterile 
protection from this analysis indicated that responses exceeding a 
thousand were likely required for sterile protection.9,15 This target 
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large family of higher primate adenoviruses.25 Three vectors, C6, 
C7 and C9 (also called AdC68) from the Wilson lab were assessed 
initially followed by AdCh63 and AdCh3 from Okairos. Using 
these vectors we made several observations.27,28 The safety of these 
vectors in mice, macaques and, recently in humans has been very 
similar to that of human adenovirus vectors suggesting that these 
might be suitable for widespread use. The T-cell immunogenicity 
of some of these vectors matched or even exceeded the immu-
nogenicity of the standard Ad5 vector used as a comparator. For 
example in the P. berghei model immunogenicity of simian ade-
noviral vectors AdC7, AdC9 (also called AdC68)28 and AdCh63 
(unpublished) was as great as that of Ad5 and considerably stron-
ger than with the poxviruses FP9 and MVA. For the first time it 
was possible to induce single dose high level protective efficacy 
against sporozoite challenge in the P. berghei model by using sim-
ian adenoviral vectors. Moreover, boosting these responses with 
MVA led to greater and more durable immunogenicity and also 
more durable efficacy against sporozoite challenge.50 The latter 
may relate to a more polyfunctional phenotype of the CD8± T-cell 
responses post-boosting with a large proportion of IL2 positive 
cells observed post- but not pre-boosting with MVA.
The vector chosen for clinical assessment in malaria was the 
AdCh63 vector, one of the species E adenoviruses. This was found 
to grow well in HEK293 cells and recombinants have been stable 
on repeated passage. The prevalence of antibodies to AdCh63 was 
assessed in Kenyan children using a neutralisation assay. It was 
found that 23% of the children (aged 1–6 years) had high-titer 
neutralizing antibodies to AdHu5, but only 4% had high-titer 
neutralizing antibodies to AdCh63.29 An increasing number of 
simian adenoviruses are now being reported of several different 
species suggesting that there will be sufficient different vector 
backbones available to allow different ones to be used for a variety 
of different diseases. Recently, progress in the clinical develop-
ment of the simian AdCh3 vector as a vaccine against hepatitis C 
has been reported.30
Vectors for Blood-Stage Malaria
Early evidence that cellular immunity was relevant to protection 
in some murine malaria models was followed by the demonstra-
tion that repeated low dose inoculations of blood-stage parasites 
appeared to induce protection in human volunteers in the absence 
of detectable antibodies.31 Very recently the induction of some cel-
lular immunity to blood-stage antigens by inducing strong immu-
nity with viable sporozoites administered with chloroquine in 
human volunteers, also supported the potential importance of T 
cells at the blood-stage in P. falciparum malaria.32 This sort of evi-
dence led to exploration of the capacity of viral vectored vaccines 
to produce immunity to blood-stage malaria in rodent models. 
Recently Draper et al.3 identified a powerfully protective regime 
for P. yoelii using an adenovirus prime followed by an MVA boost 
(Ad-M) using the 42Kd C-terminal portion of the classic blood-
stage antigen MSP1. This is of course an excellent regime for 
inducing powerful cellular immunity but the protection observed 
against blood-stage parasite challenge was entirely antibody-
mediated. Strong antibody responses were indeed induced by this 
was sobering in that very few vaccinees administered any type of 
vaccination regime in malaria or any other disease,16 reached this 
threshold at the time.
This led to renewed interest in using potentially more potent 
adenoviral vectors to try to prime more potent T-cell responses 
than DNA or Fowlpox. Initial prime-boost studies with ade-
novirus-MVA regimes in mice had shown promise in the 
P. berghei model17 and adenovirus used alone had shown good 
protection against P. yoelii liver-stages.18 Use of adenovirus vectors 
also offered a potential improvement in two other aspects of the 
immune responses induced by the first generation (DNA-MVA) 
and second generation (FP9-MVA) regimes. One of these is a 
greater ability of adenoviral vectors to induce antibody responses: 
DNA and poxvirus vectors induced only weak antibody responses 
even in heterologous prime boost regimes.7 The other, of greater 
relevance to protective liver-stage immunity was the greater capac-
ity of adenoviral vectors to induce CD8± rather than CD4± T-cell 
responses. DNA-MVA regimes in the clinic induced predomi-
nantly CD4± T-cells7 and although FP9-MVA was better19 the 
predominant response was still clearly CD4 biased.
Simian Adenoviral Vectors as Malaria Vaccines
A major concern with the use of human adenoviral vectors for 
malaria in African was the recognition that levels of anti-vector 
immunity were particularly high in African populations. For 
example the prevalence of antibodies to the most widely used and 
very potent vector Ad5 was reported as 80% and 85% in Southern 
and west African populations, respectively.20
Also, a non-significant trend towards negative efficacy in the 
HIV vaccine STEP trial21 also suggested that there might be some 
safety concern with the widespread used of Ad5 vectors in Africa 
where HIV is prevalent. Reassuringly, however, further follow up 
of the STEP trial cohort and detailed immunological efforts22,23 all 
now support the safety of Ad5 vectors. Yet the potentially imped-
ing effect of anti-vector immunity on vaccine potency remains an 
issue for malaria, particularly if high level potency is required for 
efficacy as suggested by the TRAP studies. One option is to use less 
prevalent adenoviral vectors such as Ad35, and this option is being 
pursued by a Crucell-NIH collaboration, but Ad35 vectors appear 
substantially less potent than Ad5, at least in pre-clinical studies.24 
Therefore, the option of using adenoviral vectors of simian origin 
(Fig. 1) to which humans have much lower levels of anti-vector 
immunity appeared particularly attractive for malaria.
For clinical use a viral vector must display not just good 
potency, but also genetic stability in repeated passage and a high 
viral yield in a usable GMP-approved cell line to allow large scale 
manufacture. Extensive studies by groups in the US25 and in 
Italy26 have led to the identification of several potentially suitable 
adenoviral vectors of chimpanzee origin. Our group in Oxford 
has collaborated with both the University of Pennsylvania and 
Okairos (Rome, Italy) groups to assess several simian vectors with 
malaria inserts. Phylogenetic analysis of the hexons of simian and 
human adenoviruses (Fig. 1) shows substantial overlap indicating 
that there is no clear sequence feature that distinguished a sim-
ian from a human adenovirus: in fact these sequences suggest one 
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to the C-terminal fragments and T cells to conserved domains. It 
was found that a variety of simian adenoviral vectors could act as 
good priming agents and heterologous adenoviral vector strains 
were able to boost antibodies as well as recombinant MVA. Strong 
cross-strain growth inhibitory activity was found associated with 
the high antibodies induced and this activity was against strains 
expressing both alleles of the highly polymorphic 42Kd fragment. 
Similar work with a biallelic AMA1 insert is in progress, also with 
promising results (Biswas et al. unpublished).
These exciting preclinical data led to generation of biallelic 
MSP1 and AMA1 constructs in the AdCh63 and MVA vectors 
and all four vaccine vectors have now completed GMP manufac-
ture prior to planned clinical trials. In view of the added protec-
tion observed in pre-clinical studies with sporozoite compared to 
blood-stage parasite challenge, the first phase IIa efficacy trials of 
these new vectors will involve a sporozoite rather than a blood-
stage parasite challenge protocol.
Clinical Development
The vectored vaccine programme at Oxford has continued 
to focus primarily on the TRAP antigens for T-cell-inducing 
regime and they could be amplified further and rendered more 
protective by the addition at the C-terminus of a core domain of 
the complement protein C4bp33 as a fusion to the MSP1 sequence. 
This ability to induce powerful protective antibodies with vec-
tored vaccines is of interest beyond malaria and potentially con-
siderably broadens the potential applications of this technology.
The T cells recognizing MSP1 induced by this Ad-M regime 
were of protective value against the liver-stage parasite as manifest 
both by reduced liver parasite burden and a greater efficacy of the 
regime against sporozoite than blood-stage parasite challenge.34 
Interestingly, part of the latter effect appeared attributable to a 
different cytokine profile induced at the blood-stage in vaccinated 
mice challenged with sporozoites rather than blood-stage para-
sites. Analysis of the protective effects of prime-boost vectored 
vaccines in the rhesus P. knowlesi challenge model led Weiss et al. 
to conclude that significant protection was being induced by the 
blood-stage antigens MSP1 and AMA1.4
Goodman et al. (submitted 2009) have recently taken this 
approach forward to blood-stage P. falciparum antigens and have 
generated a novel MSP1 insert comprising two allelic 42Kd frag-
ments placed C-terminal to four relatively conserved domains of 
this large molecule, with the aim of inducing protective antibodies 
Figure 1. Phylogenetic tree of hexon amino acid sequences of various human and chimpanzee adenoviruses. For clarity all human strains are prefixed 
“AdHu”, thus Ad5 = AdHu5, and all chimpanzee vectors prefixed AdCh6, thus AdC6 = AdCh6. (Gilbert SC, unpublished).
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product with the ME-TRAP vectors. Adenoviral vectors have 
been used as mixtures in several previous HIV vaccine trials21 
without evidence of interference or antigenic competition, and 
MVA has the capacity to express multiple antigens from the same 
recombinant virus.
In parallel, two groups have been assessing human adenoviral 
vectors expressing CSP and/or AMA1 in US-based clinical trials. 
The US Navy-Genvec program using Ad5 vectors is described else-
where in this volume and an NIH-Crucell collaboration has initi-
ated a phase I clinical trial of an Ad35 vector expressing CSP.39
The Oxford-Okairos program aims to initiate the first phase 
Ib trials of the simian adenovirus-MVA approach in a malaria 
endemic area of Africa in late 2009 with support from the 
European and Developing Countries Clinical Trials Partnership 
and other funders.
Towards Higher Efficacy: Combination Approaches
Although significant efficacy in clinical trials has now been 
achieved with several vectored vaccine regimes encoding 
ME-TRAP the levels attained are probably still insufficient 
for deployment of this single antigen vaccine on its own.40 But 
upcoming trials of blood-stage vectors may well lead to further 
efficacy and a combination of TRAP-expressing vectors and a 
blood-stage antigen vector may be more efficacious as suggested 
by several preclinical studies.
Another approach would be to assess the utility of combining 
the two existing subunit vaccines that show significant efficacy 
in human, RTS,S in adjuvant and TRAP-expressing vectors. 
RTS,S in the adjuvants AS01 and AS02 generates sterile protec-
tive immunity in some 32–50% of vaccines in sporozoite chal-
lenge trials2 and similar levels of field efficacy in some41 phase IIb 
studies in Africa.42,43 Immunological analysis indicates strongly 
that antibodies are the likely main protective mechanism as 
T-cell responses induced are very modest.44,45 Hence, this is an 
anti-sporozoite vaccine whereas vectored TRAP-based vaccines 
are anti-liver stage. We recently assessed in a pre-clinical P. ber-
ghei model in mice whether combined use of a protein-adjuvant 
based anti-sporozoite vaccine could add to the partial efficacy of 
a vectored vaccine against the liver-stage parasite.46
The results were striking (Fig. 2). Each vaccine individually 
afforded 33–35% sterile efficacy but the combination showed 
90% sterile efficacy against sporozoite challenge. Immunological 
analysis showed that the combination induced both the antibody 
response induced by the protein-adjuvant vaccine plus the T-cell 
response induced by the vectors.46 Hence it appears that there 
can be synergistic efficacy with this approach, probably resulting 
from a substantial reduction in sporozoite number effected by 
the antibodies making it much easier for the T cells to clear a far 
smaller number of infected liver cells. Data of this type make a 
compelling case for assessing RTS,S and TRAP vectors together 
in humans. Interestingly, the MVA vector itself has been found 
to have significant adjuvant activity when it is used in a mixture 
with a co-administered protein, at least in pre-clinical studies, 
and if this adjuvantation is also found in humans it may facilitate 
further combination vaccine strategies.47
vaccines targeting the liver-stage. This is supported by data 
from both DNA-MVA and FP9-MVA trials that found signifi-
cant efficacy with a TRAP insert but no efficacy with CSP as an 
insert.8,9,35 This contrasts with the success of RTS,S as a protec-
tive CSP-based antibody inducing vaccine. However, although 
CSP is the major coat protein on the sporozoite, recent evidence 
suggests that TRAP may be a better target of protective T cells, 
consistent with the vectored vaccine clinical trial data. Firstly, 
analysis of the time course of expression of TRAP and CSP 
by P. falciparum in cultured human hepatocytes found more 
durable expression of the former, while CSP disappeared rap-
idly.36 Secondly, population genetic analysis searching for evi-
dence of selection in the patterns of polymorphism observed in 
these two genes found stronger evidence that coding variation 
in TRAP reflected selection, consistent with immune attack 
from T cells.37
Several challenges were faced in translating the promising 
pre-clinical data with simian adenoviruses to phase I/II trials. 
A set of simian vectors that showed promise in malaria and were 
owned by the University of Pennsylvania were in-licensed by 
GSK Biologicals and became unavailable to the Oxford malaria 
programme. Fortunately, a more promising vector was available 
from Okairos (Rome, Italy), AdCh63, and ME-TRAP recombi-
nants showed not only excellent genetic stability but high yields 
in the HEK293 cell line without generating any replication com-
petent adenovirus. Studies of the prevalence of neutralizing anti-
bodies to this chimpanzee virus in the UK (unpublished) and 
also at a malaria vaccine trial site in Kilifi, Kenya, found low 
anti-vector prevalences, well below the rates for Ad5 antibodies.29 
This AdCh63 vector encoding ME-TRAP was then manufac-
tured to GMP standard at the University of Oxford’s Clinical 
Biomanufacturing Facility and approved for clinical testing in 
2007 by UK regulatory and ethical review committees, the first 
clinical trial of any simian adenoviral vector. During the phase 
I trial data emerged on a possible, albeit non-statistically signifi-
cant, increased incidence of HIV infections in as subset of vac-
cines administered an HIV vaccine comprising three different 
Ad5 vectors encoding HIV antigens.21 This had no impact on the 
continuation of the AdCh63 malaria trial and recent follow-up 
data support the view that the slightly increased infection rate in 
the HIV STEP trial was likely a chance occurrence.
A dose escalation phase I study and phase IIa sporozoite chal-
lenge study of AdCh63-MVA vaccinees have now been undertaken 
with very encouraging results. In particular T-cell immunogenic-
ity with AdCh63-MVA regimes is very substantially higher than 
with any previously assessed prime-boost regimes and many-fold 
greater that immunogenicities reported for adenovirus vectors 
used alone, or even DNA prime-adenovirus boost regimes,38 in 
HIV vaccine trials (O’Hara G et al., unpublished).
Encouraged by these safety, immunogenicity and efficacy find-
ings with ME-TRAP as an insert both MSP1 and AMA1 inserts 
have been successfully manufactured to GMP standard (Draper 
S et al., unpublished) in the same simian adenoviral and MVA 
vectors and will soon enter clinical testing. If either or both of 
these new blood-stage vectored vaccine regimes show efficacy in 
phase IIa testing the objective would be to develop a combination 
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T-cell-inducing subunit vaccine providing repeatable, albeit par-
tial, efficacy in vaccine trials, but success in other diseases should 
be close.
It is interesting to reflect on the comparative performance of 
DNA vaccines and viral vectors in human vaccine trials. Ten years 
ago there was enormous interest in the possibility that plasmid 
DNA vaccines48 could provide an approach to inducing easily 
strong cellular as well as antibody responses in humans. Although 
those hopes have been dashed, viral vectors are now showing the 
performance that was anticipated by enthusiastic advocates of 
DNA vaccination. Equally importantly, substantial progress has 
been achieved in overcoming the challenge for viral vectors of 
genetic stability, large scale low cost manufacturing and avoiding 
anti-vector immunity. We are even gaining important insights from 
the field of innate immunity about the diverse pattern recognition 
receptors that underlie the remarkable potency of some vectors.49 
As reviewed recently, viral vectors now present a major option for 
controlling diseases ranging from HIV, TB and malaria to dengue, 
Japanese encephalitis, Ebola and pandemic influenza.51
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Concluding Remarks
The progress with improved immunogenicity and efficacy of vec-
tored vaccine regimes supports the view that these should be an 
important future component of highly effective deployable malaria 
vaccines. The immunogenicity of T-cell responses now being 
observed in malaria are about five to 10 fold higher than the best 
responses seen with earlier generation candidates and, importantly, 
improved immunogenicity continues to correlate with enhanced 
efficacy. However, the evidence that very strong immunogenicity 
will be required for sterile protection provides a sobering perspec-
tive on the challenges ahead.
More broadly this progress in malaria may have useful implica-
tions for other fields. In the heavily funded area of HIV vaccine 
development there was considerable despondency when a vaccina-
tion regime deploying only Ad5 adenovirus vectors failed to show 
any protective efficacy.21 However the mean T-cell response in vac-
cinees to each antigen with this (non heterologous prime-boost) 
regime was of the order of 300 SFU/million PBMCs. This is lower 
that the malaria field achieved with first generation prime-boost 
vectors and much lower that in recent malaria trials. This provides 
an opportunity for the HIV field to adopt regimes that will allow 
the protective efficacy of broader and more abundant T cells to be 
assessed. Similarly, in TB and other disease areas where efficacy 
is more difficult and expensive to assess the differential abilities 
of adenovirus and MVA to prime and boost efficiently may be of 
value for the design of new vectored vaccination regimes. For the 
moment, malaria appears to provide the only clear example of a 
Figure 2. Analysis of the immunogenicity and protective efficacy of vectored vaccines and protein/adjuvant vaccines targeting the sporozoite and 
liver-stage of malaria, used singly and as a combination. The liver-stage vaccine is a fowlpox-MVA prime-boost regime encoding the circumsporozoite 
protein of P. berghei; the sporozoite vaccine is a recombinant hepatitis B core particle expressing the central repeats of the same protein. Sterile effi-
cacy (protection) against sporozoite challenge is shown in the upper panel table. Immunogenicity results for T-cell responses and antibody as measured 
by ELISPOT and ELISA assays, respectively, are shown in the lower panel.46
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